Beyond Pancreatic Cancer: Daraxonrasib Demonstrates Targeted Efficacy Against RAS-Mutant Lung Tumors

In a promising expansion for precision oncology, the novel targeted therapy daraxonrasib (marketed under the brand name Rasonque) is demonstrating significant activity against advanced non-small-cell lung cancer (NSCLC). Developed as a multi-selective RAS(ON) inhibitor, the oral drug recently made headlines by earning U.S. Food and Drug Administration (FDA) approval for previously treated metastatic pancreatic ductal adenocarcinoma. Clinical investigators are expanding its therapeutic scope, targeting oncogenic RAS mutations that drive nearly 30% of all non-small-cell lung malignancies.

Targeting the "Undruggable" Driver: Historically, RAS gene mutations—outside of specific subtypes like KRAS G12C—were considered notoriously difficult to target directly with pharmaceuticals. Daraxonrasib overcomes this structural barrier by functioning as a "molecular glue," locking onto active RAS(ON) state complexes to inhibit downstream cell proliferation across multiple RAS variants, including G12D and G12V mutations.

According to clinical trial results published in the New England Journal of Medicine and reported by Nature, a Phase 1/2 multicenter trial evaluated daraxonrasib in patients with advanced RAS-mutant NSCLC whose disease had progressed following standard platinum-based chemotherapy and anti-PD-(L)1 immunotherapy. In the selected docetaxel-naive dose expansion group receiving 160 mg to 220 mg daily, 42% of patients achieved a confirmed objective response rate (ORR), with an overall disease control rate of 89%. These patients experienced a median progression-free survival (PFS) of 8.3 months and a median overall survival (OS) of 16.0 months.

Clinical Trial Parameter	Phase 1/2 NSCLC Trial (RMC-6236-001)	Phase 3 Comparative Study (RASolve-301)
Target Patient Population	Previously treated advanced RAS-mutant NSCLC	Previously treated advanced RAS-mutant NSCLC
Primary Endpoint	Safety, tolerability & Objective Response Rate (ORR)	Overall Survival (OS) & Progression-Free Survival (PFS)
Efficacy Signal	42% confirmed ORR in key docetaxel-naive subgroup	Under active evaluation vs. standard chemotherapy
Comparator Arm	Dose-escalation & single-agent expansion cohorts	Standard-of-care intravenous docetaxel chemotherapy
Dosing Regimen	200 mg once-daily oral administration	200 mg once-daily oral administration

The encouraging efficacy and manageable safety profile observed in early-phase evaluation have laid the ground for RASolve-301, an ongoing, randomized Phase 3 trial. This pivotal study directly compares daily oral daraxonrasib against standard intravenous docetaxel chemotherapy in a broader cohort of patients with RAS-mutant NSCLC. If Phase 3 results mirror early clinical findings, daraxonrasib could establish a new targeted standard of care for lung cancer patients who currently lack effective biomarker-driven treatment options.